吡咯替尼联合卡培他滨治疗人表皮生长因子受体2阳性乳腺癌脑转移患者(PERMEATE):多中心、单臂、双队列、2期试验
这项多中心单臂双队列2期试验纳入78例HER2阳性乳腺癌脑转移患者,接受吡咯替尼联合卡培他滨治疗。队列A(未接受放疗)颅内客观缓解率为74.6%,队列B(放疗后进展)为42.1%。最常见≥3级不良事件为腹泻。作者认为该联合方案值得在随机对照试验中进一步验证。
要点
- 队列A(未放疗)颅内客观缓解率74.6%(95%CI 61.6-85.0),队列B(放疗后进展)为42.1%(95%CI 20.3-66.5)。
- 队列A中≥3级腹泻发生率为24%(14例),队列B为21%(4例)。
- 队列A中治疗相关严重不良事件2例(3%),队列B为3例(16%),无治疗相关死亡。
核心结论
- 据作者所知,这是首个前瞻性研究显示吡咯替尼联合卡培他滨在HER2阳性乳腺癌脑转移患者中具有活性和安全性,尤其是在未接受放疗的人群中。
- 作者认为该联合方案值得在随机对照试验中进一步验证。
研究设计与样本
- 多中心、单臂、双队列、2期试验,在中国八家三级医院开展。
- 纳入年龄≥18岁、ECOG体能状态0-2分的HER2阳性乳腺癌脑转移患者:队列A为未接受放疗的脑转移,队列B为放疗后进展。
- 治疗方案:吡咯替尼400 mg口服每日一次,卡培他滨1000 mg/m²口服每日两次,连用14天休息7天,每3周为一周期,直至疾病进展或不可耐受毒性。
- 主要终点为研究者根据RECIST 1.1评估的确认颅内客观缓解率。
- 2019年1月29日至2020年7月10日共入组78例女性;至少接受一剂研究药物的患者纳入活性和安全性分析。
主要发现
- 队列A中51/59例(86%)有既往曲妥珠单抗暴露,队列B中18/19例(95%)有既往曲妥珠单抗暴露。
- 中位随访时间15.7个月(IQR 9.7-19.0)。
- 队列A颅内客观缓解率为74.6%(95%CI 61.6-85.0;44/59例),队列B为42.1%(95%CI 20.3-66.5;8/19例)。
- 最常见的≥3级治疗中出现的不良事件为腹泻:队列A 14例(24%),队列B 4例(21%)。
- 队列A中2例(3%)发生治疗相关严重不良事件,队列B中3例(16%);无治疗相关死亡。
局限性
- 作者结论指出该联合方案值得在随机对照试验中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with HER2-positive metastatic breast cancer have a high risk of developing brain metastases. Efficacious treatment options are scarce. We investigated the activity and safety of pyrotinib plus capecitabine in patients with HER2-positive metastatic breast cancer and brain metastases. METHODS: We did a multicentre, single-arm, two-cohort, phase 2 trial in eight tertiary hospitals in China. Patients aged 18 years or older who had radiotherapy-naive HER2-positive brain metastases (cohort A) or progressive disease after radiotherapy (cohort B), with an Eastern Cooperative Oncology Group performance status of 0-2, received pyrotinib 400 mg orally once daily, and capecitabine 1000 mg/m2 orally twice daily for 14 days, followed by 7 days off every 3 weeks until disease progression or unacceptable toxicity. The primary endpoint was confirmed intracranial objective response rate by investigator assessment according to the Response Evaluation Criteria In Solid Tumours (version 1.1). Activity and safety were analysed in patients with at least one dose of study drug. The study is ongoing, but recruitment is complete. The study is registered with ClinicalTrials.gov, NCT03691051. FINDINGS: Between Jan 29, 2019, and July 10, 2020, we enrolled 78 women: 51 (86%) of 59 patients in cohort A and 18 (95%) of 19 patients in cohort B had previous exposure to trastuzumab. Median follow-up duration was 15·7 months (IQR 9·7-19·0). The intracranial objective response rate was 74·6% (95% CI 61·6-85·0; 44 of 59 patients) in cohort A and 42·1% (20·3-66·5; eight of 19 patients) in cohort B. The most common grade 3 or worse treatment-emergent adverse event was diarrhoea (14 [24%] in cohort A and four [21%] in cohort B). Two (3%) patients in cohort A and three (16%) in cohort B had treatment-related serious adverse events. No treatment-related deaths occurred. INTERPRETATION: To our knowledge, this is the first prospective study showing the activity and safety of pyrotinib plus capecitabine in patients with HER2-positive breast cancer and brain metastases, especially in radiotherapy-naive population. This combination deserves further validation in a randomised, controlled trial. FUNDING: National Cancer Centre Climbing Foundation Key Project of China, Jiangsu Hengrui Pharmaceuticals. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial. Lancet Oncol. 2022. PMID: 35085506. doi:10.1016/S1470-2045(21)00716-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。